Amgen Inc (AMGN): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Amgen ( AMGN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.7%. By the end of trading, Amgen rose $2.00 (2.1%) to $98.28 on heavy volume. Throughout the day, 6,248,163 shares of Amgen exchanged hands as compared to its average daily volume of 3,846,300 shares. The stock ranged in a price between $95.06-$99.12 after having opened the day at $97.08 as compared to the previous trading day's close of $96.28. Other companies within the Health Care sector that increased today were: Oramed Pharmaceuticals ( ORMP), up 25.6%, Cytokinetics ( CYTK), up 22.0%, Escalon Medical Corporation ( ESMC), up 21.5% and Novogen ( NVGN), up 18.9%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $74.4 billion and is part of the drugs industry. The company has a P/E ratio of 16.8, below the S&P 500 P/E ratio of 17.7. Shares are up 11.7% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the negative front, Pingtan Marine Enterprise ( PME), down 64.8%, Idenix Pharmaceuticals ( IDIX), down 30.7%, Genvec ( GNVC), down 17.4% and Biosante Pharmaceuticals ( BPAX), down 16.7% , were all laggards within the health care sector with Allergan ( AGN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers